World's Best Scientists 2026 revealed!
Özlem Türeci

Özlem Türeci

D-Index & Metrics

Biology and Biochemistry

D-Index
85
Citations
59327
World Ranking
3051
National Ranking
228

Overview

Özlem Türeci is affiliated with BioNTech in Germany and has contributed extensively to the field of Medicine, focusing primarily on Infectious Diseases, Oncology, and Immunology. Their work spans multiple areas including Molecular Biology and Animal Science and Zoology, reflecting a broad research interest within biomedical sciences.

Their recent published papers include:

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020), New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020), New England Journal of Medicine
  • COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020), Nature
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020), Nature
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (2023), Nature

Özlem Türeci frequently collaborates with several researchers in their field. Notable co-authors include:

  • Uğur Şahin
  • Alexander Muik
  • Kena A. Swanson
  • Nicholas Kitchin
  • David Cooper

Their publications are often found in the following venues:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • Nature
  • Regular and Young Investigator Award Abstracts
  • New England Journal of Medicine

Their research contributions cover several main topics within the biomedical sciences, including:

  • SARS-CoV-2 and COVID-19 Research
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Animal Virus Infections Studies

The scientist has published over 200 works in the field of Medicine, with a significant focus on Infectious Diseases through more than 100 publications. Oncology and Immunology are also key areas of study with dozens of related publications. The topics frequently engage with immunotherapeutic methods, viral infection mechanisms, and vaccine development, reflecting current priorities in biomedical research.

Best Publications

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

    Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

    Ugur Sahin;Evelyna Derhovanessian;Matthias Miller;Björn-Philipp Kloke

  • mRNA-based therapeutics — developing a new class of drugs

    Ugur Sahin;Katalin Karikó;Özlem Türeci

  • COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

    Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  • Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

    Lena M. Kranz;Mustafa Diken;Heinrich Haas;Sebastian Kreiter

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

    Yao-Tseng Chen;Matthew J. Scanlan;Ugur Sahin;Özlem Türeci

  • Human neoplasms elicit multiple specific immune responses in the autologous host.

    Ugur Sahin;Ozlem Tureci;Holger Schmitt;Bjorn Cochlovius

  • Mutant MHC class II epitopes drive therapeutic immune responses to cancer

    Sebastian Kreiter;Mathias Vormehr;Niels van de Roemer;Mustafa Diken

  • Personalized vaccines for cancer immunotherapy.

    Ugur Sahin;Özlem Türeci

  • Exploiting the mutanome for tumor vaccination

    John C. Castle;Sebastian Kreiter;Jan Diekmann;Martin Löwer

  • An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

    Ugur Sahin;Petra Oehm;Evelyna Derhovanessian;Robert A. Jabulowsky

  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

    Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

    Stephen J. Thomas;Edson D. Moreira;Nicholas Kitchin;Judith Absalon

  • BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

    Ugur Sahin;Alexander Muik;Isabel Vogler;Evelyna Derhovanessian

  • Modification of antigen encoding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells

    Silke Holtkamp;Sebastian Kreiter;Abderraouf Selmi;Petra Simon

  • BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

    Annette B. Vogel;Isis Kanevsky;Ye Che;Kena A. Swanson

  • Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

    Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

  • Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.

    Alexander Muik;Ann-Kathrin Wallisch;Bianca Sänger;Kena A. Swanson

Frequent Co-Authors

Ugur Sahin
Ugur Sahin Johannes Gutenberg University of Mainz
Michael Pfreundschuh
Michael Pfreundschuh Saarland University
Christoph Huber
Christoph Huber BioNTech (Germany)
Yao-Tseng Chen
Yao-Tseng Chen Cornell University
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
John C. Castle
John C. Castle Monte Rosa Therapeutics
Andreas Kuhn
Andreas Kuhn University of Hohenheim
Philip R. Dormitzer
Philip R. Dormitzer Pfizer (United States)
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Pei-Yong Shi
Pei-Yong Shi GlaxoSmithKline (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Özlem Türeci

Trending Scientists

Recently Published Articles